Biopharmaceuticals Contract Manufacturing Market Report 2026

The biopharmaceuticals contract manufacturing market size has grown rapidly in recent years. It will grow from $22.22 billion in 2025 to $24.62 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to expansion of biologics drug pipelines, rising r&d investments by biopharmaceutical companies, limited in-house manufacturing capacity, growth in clinical trial activities, increasing regulatory standardization.

The biopharmaceuticals contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $38.22 billion in 2030 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to increasing demand for biosimilars manufacturing, rising investments in advanced biologics facilities, expansion of gene and cell therapy production, growing focus on flexible manufacturing models, increasing partnerships between pharma and CDMOs. Major trends in the forecast period include increasing outsourcing of biologic drug production, rising demand for monoclonal antibody manufacturing, growing use of single-use bioprocessing systems, expansion of fill-and-finish capabilities, enhanced focus on regulatory-compliant manufacturing.

The rising demand for personalized medicine is anticipated to significantly boost the growth of the biopharmaceutical contract manufacturing market in the coming years. Personalized medicine represents a tailored healthcare approach that considers individual patient characteristics, such as genetics, environment, and lifestyle, to improve treatment effectiveness and outcomes. Several factors are driving the demand for personalized medicine, including advancements in genomics, increased patient empowerment, and enhanced treatment efficacy. Contract manufacturers are able to develop customized production processes that meet the specific needs of personalized therapies, accommodating small batch sizes and unique formulations. For example, a report from the Personalized Medicine Coalition, a U.S.-based non-profit organization, noted that in February 2024, the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, compared to just six in 2022. Consequently, the increasing demand for personalized medicine is fueling the growth of the biopharmaceutical contract manufacturing market.

Major companies in the biopharmaceutical contract manufacturing sector are increasingly focusing on monoclonal antibodies developed using advanced go-to cell line platforms to deliver efficient and reliable services. These standardized and optimized platforms enable faster cell line development and improved production of biotherapeutics. For instance, in September 2023, KBI Biopharma Inc., a US-based life sciences company, launched SUREmAb, a monoclonal antibody solution built on its SUREtechnology Platform to enhance development and manufacturing efficiency. The offering supports rapid research cell bank creation within nine weeks and accelerates the transition from DNA to GMP drug substance in about 11 months, while the integration of KBI Biopharma and Selexis further streamlined operations and optimized monoclonal antibody development.

In May 2025, PCI Pharma Services Inc., a U.S.-based contract development and manufacturing organization (CDMO) specializing in drug development, sterile fill-finish, and advanced drug delivery, acquired Ajinomoto Althea, Inc. for an undisclosed amount to expand its U.S. sterile manufacturing footprint and scale advanced injectable and biologics production capabilities, including prefilled syringes, cartridges, and high-potency formats, thereby enhancing support for biopharmaceutical customers and strengthening its manufacturing network; Ajinomoto Althea is a U.S.-based sterile fill-finish CDMO that offers aseptic fill-finish and formulation services for clinical and commercial-stage biopharmaceutical products, with expertise in complex injectables such as customized oligonucleotides, peptides, and other advanced formulations.

Major companies operating in the biopharmaceuticals contract manufacturing market include Boehringer Ingelheim GmbH, Lonza Group Ltd., Inno Biologics Sdn Bhd, Rentschler Biopharma SE, Samsung Biologics Co. Ltd., AGC Biologics, ProBioGen AG, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific Inc., Binex Co. Ltd., AbbVie Inc., Catalent Inc, Pfizer Inc., Merck KGaA, Pressure BioSciences, Novartis International AG, Cambrex Corporation, Emergent BioSolutions Inc., JRS Pharma GmbH & Co. KG, WuXi Biologics, Siegfried Holding AG, Toyobo Co. Ltd., ADMA Biologics Inc., UCB S.A., AstraZeneca PLC, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Shire Pharmaceuticals LLC, Baxter International Inc., Becton Dickinson and Company, Polyphor Ltd., Patheon Inc., Alcami Corporation

North America was the largest region in the biopharmaceutical contract manufacturing market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global biopharmaceuticals contract manufacturing market forecast period. The regions covered in the biopharmaceuticals contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biopharmaceuticals contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biopharmaceutical contract manufacturing market includes revenues earned by entities providing services such as formulation development, GMP manufacturing, and supply chain management. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.